AACR 24
We’re thrilled to be at AACR24 in San Diego, showcasing our latest research with a strong presence through seven posters. We can’t wait to connect with you at our presentations. See below for where to find us! Review our 7…
Primary Screening Case Study
At Pelago Bioscience, we offer a high-throughput screening service based on CETSA® – a transformative, label-free assay for target engagement quantification in physiologically relevant contexts. This case study illustrates how employing high-throughput screening with CETSA can deliver…
ELRIG Research & Innovation 2024
We are thrilled to share that we will be showcasing our high-throughput services at ELRIG Research & Innovation 2024 in Manchester! Join us at The University of Manchester to explore how our offerings can support your Drug Discovery journey. We…
UNIVERSITY OF EDINBURGH ACKNOWLEDGES PELAGO PATENT AND USE OF CETSA® PROCESS
Pelago Bioscience AB is a Discovery Research Partner serving the Drug Discovery community quantifying cellular target engagement of potential novel therapeutics from target validation to Candidate Drug nomination using our patented CETSA® technology platform. In connection with…
Pelago Bioscience Featured in Top Ten Most Popular Drug Hunter Resources of 2023
We’re delighted to share that our commitment to advancing Drug Discovery has earned us a spot in the “Top Ten Most Popular Drug Hunter Resources of 2023.” The insightful article, “Drug Target Identification Methods After a Phenotypic Screen,” published in…
Drug Discovery Biology & Medicinal Chemistry Strategy Meetings East Coast USA
We are thrilled to join the Drug Discovery Biology & Medicinal Chemistry Strategy Meetings hosted by Proventa International at Cambridge, MA at Le Meridien Hotel. We are excited to share our insights and experiences in the drug discovery field with…
Discovery US 2023
The starting point for any desired biological effect is a drug-target interaction, an interaction that can be studied in a live cellular setting using the CETSA® technology. Drug hunters are now expanding the therapeutic target space to include harder to…
ELRIG – DRUG DISCOVERY 2023
Learn how Pelago Bioscience and our technology CETSA®, Cellular Thermal Shift Assay can help you assess target engagement, and bring your projects forward with confidence through: • Physiologically relevant, robust data • Completely label-free • Transferability across matrices…
6th Targeted Protein Degradation Summit
Protein degradation is a novel modality with the potential to tackle therapeutically interesting proteins previously seen as undruggable. In this area, CETSA® is a powerful technology for identifying binders, investigating target engagement and the mechanism of action of the protein…
New CETSA® Publication – Quantitative target engagement of RIPK1 in human whole blood
In a recent collaboration between AbbVie Chemical Biology and Pelagoo Bioscience, CETSA® was applied to quantify direct target engagement of several inhibitors in unprocessed human whole blood. The study investigated RIPK1 as a proof-of-concept target, showcasing the high sensitivity and…
BioJapan 23
CETSA® by Pelago Bioscience is a well-proven, best-in-class technology used to assess cellular protein-compound binding in cell. CETSA® can be applied throughout all steps of the drug discovery value chain for screening, hit confirmation and selectivity. Because neither the ligand…
Unlocking Proteomics: Pelago Bioscience’s HUPO Award-Winning CETSA® approach
Pelago Bioscience proudly receives the HUPO Science and Technology Award, celebrating our pioneering work in CETSA (Cellular Thermal Shift Assay) and the Pelago team work including Alexey Chernobrovkin and Tomas Friman. This technology provides invaluable insights into proteomics, and how…
Impilo & Pelago Bioscience Partnership!
Impilo invests in Pelago Bioscience AB and enters a partnership to accelerate Pelago’s growth. Founded in 2013, Pelago is a fast-growing drug discovery focused contract research organisation offering services based on the patented CEllular Thermal Shift Assay (CETSA®) technology…
CETSA® to Study the Mechanism of Action of Brefeldin A
Webinar Overview In this webinar, you will find the details of the project where CETSA® Explore was leveraged to study the biological mechanism of the fungal polyketide lactone Brefeldin A (BFA) in human THP-1 cells. Fungal genomes encode a…
New CETSA® Publication – A Shift in Thinking
We are thrilled to share our latest publication in the journal “ACS Medicinal Chemistry Letters” titled – A Shift in Thinking: Cellular Thermal Shift Assay-Enabled Drug Discovery. In this study, we highlighted recently published applications of CETSA® and how the…
CETSA® Conference, september 28
Pelago Bioscience is bringing together the CETSA® community to inspire, learn and unleash drug discovery. As Pelago is expanding its portfolio of services and technologies, we remain committed to empowering our partners in accelerating drug discovery. As a part…
Webinar DTR
The Cellular Thermal Shift Assay (CETSA®) is an easy and proven method to demonstrate ligand-protein interactions in living cells and can be used without the need of any modifications to the ligand or protein. Quantification methods like PerkinElmer’s no-wash immunoassays…
Pelago Bioscience is featured in Drug Discovery World, spring edition 2021.
CETSA® by Pelago can be adapted for different applications to support any stage of the drug discovery process from low-throughput confirmation and high-throughput discovery to proteome-wide exploration – these methods rely on the same principle: measurements of the ‘thermal shift…
Press Release – New Facility
Pelago Bioscience AB expands to new facility After several years of continued growth in our current facilities Pelago Bioscience now really expands. The new building is located at Campus Solna, a rapidly developing Life Science cluster located in central…
April 7 Webinar
Confirmation of target engagement in relevant physiological environment ensures successful drug discovery and the right project prioritization. By applying CETSA®, you can make better and more informed decisions at earlier stages in your drug discovery projects. Welcome to learn from…
Gasell prize to Pelago-again
Time to celebrate – For the third year in a row, Pelago has been awarded the prestigious DI Gasell prize by the Swedish daily business newspaper Dagens Industri. This prize recognizes the fastest growing Swedish companies, with less than 1…
Pelago receives CIR (French Research Tax Credit) accreditation
We have the pleasure to announce that the French Ministry for Higher Education and Research has recognised Pelago Bioscience AB as an approved research and development service provider. This allows companies, subject to the French General Tax Code, to take…
New interesting CETSA® paper in Nature protocols
Don’t miss this new interesting CETSA® paper published in Nature Protocols. https://www.nature.com/articles/s41596-020-0310-z Are you sure? Is you target compound really theraputic? Speak to our experts Learn how CETSA® can enable your project by talking to one of our Drug Discovery…